JP2017512996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512996A5 JP2017512996A5 JP2016558687A JP2016558687A JP2017512996A5 JP 2017512996 A5 JP2017512996 A5 JP 2017512996A5 JP 2016558687 A JP2016558687 A JP 2016558687A JP 2016558687 A JP2016558687 A JP 2016558687A JP 2017512996 A5 JP2017512996 A5 JP 2017512996A5
- Authority
- JP
- Japan
- Prior art keywords
- panel
- sample
- marker
- value
- quality
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 37
- 239000003550 marker Substances 0.000 claims description 33
- 239000010836 blood and blood product Substances 0.000 claims description 32
- 229940125691 blood product Drugs 0.000 claims description 32
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 18
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 12
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 12
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 12
- 229960003104 ornithine Drugs 0.000 claims description 12
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 11
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 10
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 claims description 4
- 238000004364 calculation method Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000013480 data collection Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000012953 feeding on blood of other organism Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000013500 data storage Methods 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 238000007477 logistic regression Methods 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 238000013441 quality evaluation Methods 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161766.2 | 2014-03-26 | ||
| EP14161766 | 2014-03-26 | ||
| PCT/IB2015/052243 WO2015145387A1 (en) | 2014-03-26 | 2015-03-26 | Means and methods for determination of quality of blood samples based on metabolite panel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512996A JP2017512996A (ja) | 2017-05-25 |
| JP2017512996A5 true JP2017512996A5 (enExample) | 2018-05-17 |
Family
ID=50433941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558687A Pending JP2017512996A (ja) | 2014-03-26 | 2015-03-26 | 代謝産物パネルに基づく血液サンプルの品質の決定のための手段および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180217125A1 (enExample) |
| EP (1) | EP3123174A4 (enExample) |
| JP (1) | JP2017512996A (enExample) |
| KR (1) | KR20160146727A (enExample) |
| CN (1) | CN106415274A (enExample) |
| AU (1) | AU2015237804A1 (enExample) |
| BR (1) | BR112016021929A2 (enExample) |
| CA (1) | CA2941979A1 (enExample) |
| WO (1) | WO2015145387A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017079384A1 (en) | 2015-11-04 | 2017-05-11 | Metabolon, Inc. | Automated sample quality assessment |
| JP2020518834A (ja) * | 2017-05-02 | 2020-06-25 | リキッド バイオサイエンシズ，インコーポレイテッド | 生体試料の属性を決定するためのシステムおよび方法 |
| CA3067280A1 (en) * | 2017-06-16 | 2018-12-20 | Drk Blutspendedienst Baden-Wurttemberg-Hessen GgmbH | Method and apparatus for single tube blood donor screening |
| CN107818329B (zh) * | 2017-08-09 | 2023-04-18 | 亿纳谱（浙江）生物科技有限公司 | 一种质谱数据分析方法 |
| CN107782825A (zh) * | 2017-12-01 | 2018-03-09 | 武汉迈特维尔生物科技有限公司 | 一种基于液相色谱检测动物体中小分子代谢物的方法 |
| CN110609139B (zh) * | 2018-06-14 | 2023-06-30 | 深圳市理邦精密仪器股份有限公司 | 抗原浓度过量检测方法、装置及存储介质 |
| US20220146526A1 (en) * | 2019-05-09 | 2022-05-12 | Shimadzu Corporation | Method for evaluating sample, analysis method, method for detecting degraded sample, marker for detecting degraded blood plasma sample, and marker for detecting degraded serum sample |
| US12606858B2 (en) * | 2019-09-20 | 2026-04-21 | Charité—Universitäetsmedizin Berlin | Methods, kits and devices for measuring extracellular pyridine nucleotide |
| CN110890130B (zh) * | 2019-12-03 | 2022-09-20 | 大连理工大学 | 基于多类型关系的生物网络模块标志物识别方法 |
| CN111239283A (zh) * | 2020-02-18 | 2020-06-05 | 深圳脉图精准技术有限公司 | 焦谷氨酸作为判断代谢组学血液样本质量的质检指示物的应用 |
| JP2023532786A (ja) * | 2020-07-09 | 2023-07-31 | ヘルシンギン ユリオピスト | 試料からのｎａｄ代謝産物の量を判定する方法ならびにそれに関連する方法および使用 |
| JP7600875B2 (ja) * | 2021-06-01 | 2024-12-17 | 株式会社島津製作所 | 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法 |
| WO2023022132A1 (ja) * | 2021-08-17 | 2023-02-23 | 国立研究開発法人理化学研究所 | 成分分析装置および成分分析方法 |
| CN120142679B (zh) * | 2025-05-06 | 2026-02-17 | 南方医科大学珠江医院 | 生物标志物组合物及其在mgmt启动子甲基化检测中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008033575A2 (en) * | 2006-09-15 | 2008-03-20 | Metabolon, Inc. | Methods of identifying biochemical pathways |
| ES2529094T3 (es) * | 2009-03-04 | 2015-02-16 | John Wan | Dispositivo de recogida y ensayo de fluido biológico |
| CA2764049A1 (en) * | 2009-06-04 | 2010-12-09 | Charite Universitaetsmedizin Berlin | Means and methods for diagnosing prostate carcinomas |
| ES2647461T3 (es) * | 2009-12-18 | 2017-12-21 | F. Hoffmann-La Roche Ag | GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca |
| JP6388606B2 (ja) * | 2013-02-14 | 2018-09-12 | メタノミクス ヘルス ゲーエムベーハー | 生物学的サンプルの質を評価するための手段及び方法 |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| AU2014368412A1 (en) * | 2013-12-20 | 2016-07-07 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel |
-
2015
- 2015-03-26 EP EP15768554.6A patent/EP3123174A4/en not_active Withdrawn
- 2015-03-26 AU AU2015237804A patent/AU2015237804A1/en not_active Abandoned
- 2015-03-26 CA CA2941979A patent/CA2941979A1/en not_active Abandoned
- 2015-03-26 CN CN201580027673.9A patent/CN106415274A/zh active Pending
- 2015-03-26 WO PCT/IB2015/052243 patent/WO2015145387A1/en not_active Ceased
- 2015-03-26 US US15/128,523 patent/US20180217125A1/en not_active Abandoned
- 2015-03-26 JP JP2016558687A patent/JP2017512996A/ja active Pending
- 2015-03-26 KR KR1020167029433A patent/KR20160146727A/ko not_active Withdrawn
- 2015-03-26 BR BR112016021929A patent/BR112016021929A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bleka et al. | A comparative study of qualitative and quantitative models used to interpret complex STR DNA profiles | |
| Smith et al. | The relationship between critical velocity, maximal lactate steady-state velocity and lactate turnpoint velocity in runners | |
| JP2016505840A5 (enExample) | ||
| JP2016510414A5 (enExample) | ||
| JP2022527653A (ja) | 疾患を診断する方法 | |
| Macinnis et al. | Methods to estimate V˙ O2max upon acute hypoxia exposure | |
| JP2011248885A5 (enExample) | ||
| JP2013036832A5 (enExample) | ||
| Bouvier et al. | Utility of S100B serum level for the determination of concussion in male rugby players | |
| AU2019269742A1 (en) | Inferring selection in white blood cell matched cell-free DNA variants and/or in RNA variants | |
| Taylor et al. | Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm phase II design | |
| Xu et al. | Abnormal platelet parameters in inflammatory bowel disease: A systematic review and meta-analysis | |
| JP2009079966A (ja) | 畜肉の熟成度判定方法 | |
| Baidoo et al. | Systematic review and meta-analysis to estimate a reference range for circulating ionized magnesium concentrations in adult populations | |
| Andrés-Otero et al. | Multiple approaches to assess fourteen non-invasive serum indexes for the diagnosis of liver fibrosis in chronic hepatitis C patients | |
| Gatt et al. | From vitamin K antagonists to liver international normalized ratio: a historical journey and critical perspective | |
| Lee et al. | Clinical usefulness of international normalized ratio calibration of prothrombin time in patients with chronic liver disease | |
| RU2754776C1 (ru) | Способ клинико-лабораторного прогнозирования тяжести covid-19 | |
| JP2017083340A5 (enExample) | ||
| US10261068B2 (en) | Persevere-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype | |
| Silva et al. | Longitudinal decline of diffusing capacity of the lung for carbon monoxide in community subjects with the PiMZ α1-antitrypsin phenotype | |
| Carll et al. | Evaluation of the clinical utility of factor V, VII, and VIII assays in assessment of DIC | |
| Costa et al. | B58 LUNG IMAGING I: PHYSIOLOGIC AND CLINICAL CORRELATES: Reliability Of Estimates Of Lung Perfusion Heterogeneity Using Positron Emission Tomography (pet) | |
| Bruno et al. | Validity and Reliability of Portable Blood Lactate Analyzers: A Systematic Review with COSMIN and GRADE Assessment | |
| Sourati et al. | Assessing subsets of analytes in context of detecting laboratory errors |